GlassScriptPhysician profile
Corbin Brock Rogers
NPI 1679675433
$9,879.64
in general payments reported to CMS, 2019-2025
34 companies · $2,280 in 2025
The $2,280 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,667 · 2022: $1,812 · 2023: $1,864 · 2024: $2,256 · 2025: $2,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,652 · Consulting Fee: $500 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,652.05 |
| Consulting Fee | $500.00 |
| Education | $248.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,267.48 | 2021-2025 | |
| Janssen Biotech, INC. | $884.07 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $790.18 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $781.69 | 2022-2025 | Sotyktu |
| Incyte Corporation | $722.02 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $673.15 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $594.34 | 2022-2025 | Dupixent, Libtayo |
| Journey Medical Corporation | $558.71 | 2025 | |
| Sun Pharmaceutical Industries INC. | $487.79 | 2021-2025 | Winlevi |
| Galderma Laboratories, L.P. | $482.90 | 2021-2025 | Aklief, Oracea, Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $452.33 | 2021-2024 | Jublia |
| Genzyme Corporation | $416.06 | 2021-2025 | |
| Lilly USA, LLC | $371.68 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $316.21 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $218.05 | 2023-2025 | Zoryve |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $178.42 | 2021-2025 | |
| Ucb, INC. | $126.94 | 2022-2025 | Bimzelx |
| Biofrontera INC. | $94.48 | 2021-2025 | Bf-Rhodoled |
| Organon LLC | $82.45 | 2025 | Vtama |
| Kerecis Limited | $50.45 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Genentech USA, INC. | $46.99 | 2021-2024 | Erivedge |
| Almirall LLC | $41.73 | 2021-2022 | |
| Strata Skin Sciences, INC. | $32.16 | 2022-2025 | Xtrac |
| Krystal Biotech INC | $25.80 | 2025 | Vyjuvek |
| Organogenesis INC. | $24.38 | 2023 | Puraply |
| Lnhc, INC | $22.41 | 2025 | Zelsuvmi |
| Vyne Pharmaceuticals INC. | $21.33 | 2021 | |
| Convatec INC. | $20.12 | 2024 | |
| Kyowa Kirin, INC. | $17.92 | 2022 | |
| Verrica Pharmaceuticals INC. | $17.46 | 2023 | Ycanth |
| Dermavant Sciences, INC. | $16.35 | 2024 | Vtama |
| Ani Pharmaceuticals, INC. | $16.15 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.42 | 2025 | Nuzyra |
| Epi Health, LLC | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corbin Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.